BidaskClub downgraded shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from a hold rating to a sell rating in a research note published on Thursday morning.

A number of other equities analysts have also weighed in on the stock. ValuEngine raised shares of Intercept Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, December 1st. Leerink Swann reaffirmed a hold rating and set a $60.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, November 28th. Wedbush reaffirmed a buy rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Monday, November 20th. Needham & Company LLC reaffirmed a hold rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Finally, Cowen reaffirmed a buy rating and set a $112.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $144.13.

Intercept Pharmaceuticals (ICPT) traded up $0.22 during trading hours on Thursday, hitting $61.68. 487,934 shares of the stock were exchanged, compared to its average volume of 649,426. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a twelve month low of $54.98 and a twelve month high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.48) by $0.59. The business had revenue of $41.33 million during the quarter, compared to analyst estimates of $36.95 million. Intercept Pharmaceuticals had a negative net margin of 344.74% and a negative return on equity of 176.51%. The company’s revenue was up 697.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.59) earnings per share. research analysts anticipate that Intercept Pharmaceuticals will post -13.35 earnings per share for the current fiscal year.

In other news, CEO Mark Pruzanski sold 1,532 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total value of $90,188.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 2,566 shares of company stock valued at $151,025 over the last 90 days. Insiders own 9.20% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sphera Funds Management LTD. boosted its stake in Intercept Pharmaceuticals by 100.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $3,632,000 after acquiring an additional 15,000 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after purchasing an additional 57,149 shares during the period. Dynamic Technology Lab Private Ltd raised its holdings in shares of Intercept Pharmaceuticals by 85.6% during the second quarter. Dynamic Technology Lab Private Ltd now owns 6,798 shares of the biopharmaceutical company’s stock worth $824,000 after purchasing an additional 3,136 shares during the period. Asymmetry Capital Management L.P. acquired a new stake in shares of Intercept Pharmaceuticals during the second quarter worth $3,580,000. Finally, Senvest Management LLC acquired a new stake in shares of Intercept Pharmaceuticals during the third quarter worth $33,883,000. Hedge funds and other institutional investors own 73.80% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Intercept Pharmaceuticals (ICPT) to Sell” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/bidaskclub-lowers-intercept-pharmaceuticals-icpt-to-sell/1755848.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.